Content about biopharmaceutical

September 30, 2014

Johnson & Johnson has entered into a definitive agreement to acquire Alios BioPharma, a privately held clinical stage biopharmaceutical company focused on developing therapies for viral diseases, for approximately $1.8 billion in cash.

Johnson & Johnson has entered into a definitive agreement to acquire Alios BioPharma, a privately held clinical stage biopharmaceutical company focused on developing therapies for viral diseases, for approximately $1.8 billion in cash.

The acquisition will include Alios BioPharma's portfolio of potential therapeutics for viral infections including compound AL-8176, an orally administered antiviral therapy currently in Phase 2 studies for the treatment of infants with respiratory syncytial virus.
 

September 16, 2010

Dick's Sporting Goods announced that Jacqualyn Fouse has been elected to the company's board of...